Let’s turn type one into type none
"My involvement with JDRF increased after my two grandchildren were diagnosed. Maintaining their health is a 24 hour, seven day a week commitment for their parents... It is never ending. Society could get a better understanding of the disease, JDRF and the research, the day-to-day dilemmas and have a sympathetic ear to it until a cure is found."
Letter From Leadership

JDRF was founded on the passion of deeply committed families battling type 1 diabetes (T1D). This passion continues to fuel our organization - it is why we are focused on turning type one into type none. We take a global perspective on research, prioritizing areas that will have the greatest impact today and tomorrow, and we are continually driving progress from discoveries in the lab to new therapies that will positively impact everyone living with T1D.

In Canada, we are important players in the global research arena with the JDRF Canadian Clinical Trial Network (CCTN) and many other JDRF funded projects in leading hospitals and research universities. In 2012, JDRF received a generous $3 million gift from the WB Family Foundation to help expand CCTN. During 2013 a research competition was held, with the outcome being that three new trials will be added to CCTN in the cure area, all in western Canada. This is very exciting since it continues to build a strong, collaborative research network in Canada.

During the fall of 2013, we had a leadership transition with the departure of President and CEO, Andrew McKee. He dedicated over five years in guiding the Foundation to where it is today and we are thankful to Andrew for his tremendous work and for the seamless transition to our new President and CEO, Dave Prowten. Dave’s passion, strategic leadership and expertise in fundraising will help JDRF move to the next level.

2013 marked another successful year for JDRF with advances in research and strong fundraising performance. We are grateful for your ongoing support which was demonstrated in so many ways, and continues to inspire the staff and Board of Directors. As we look ahead to 2014, we know it will be an exciting year with advancements and meaningful scientific progress. THANK YOU for your unrelenting commitment and dedication to JDRF - you are the ones who make a difference. Doing this together, we will turn type one into type none.
“I originally got involved with JDRF about ten years ago. Two years ago my granddaughter was diagnosed. This drives it home a little closer emotionally. When you see these little kids, you want to make a difference. We need more public awareness as we work hard to raise money for research and a cure.”

Chris Vardy – Atlantic Region
Laura & Shane McFadden – South Western Ontario Region

“As a mom you are supposed to take the hurt away but this is the one thing I can’t fix. My motivation is love; for my child and all the children who are diagnosed.” - Laura

“I am motivated by my daughter’s diagnosis and the youth ambassador I heard speak three days prior to her diagnosis. I think about the next child who gets the bad news. I want to prevent and cure type 1 diabetes.” - Shane

JDRF’s diabetes research portfolio is among the most innovative in the world. It is a portfolio focused on multiple paths to a cure, on better treatments to keep people with diabetes healthier, and on research for all stages of diabetes. JDRF’s research focuses on bringing life-changing therapies to people who have been living with diabetes for years, sometimes decades; people who are newly diagnosed, both children and adults; people with complications; and people who are at risk of getting diabetes.

JDRF’s strategy is to approach research from a patient-centric perspective. All people with type 1 diabetes (T1D) want to find a cure—a cure to some can mean a pill or injection or procedure that restores their pancreas to a fully functional state. Some also define a cure as a simpler and safer alternative to insulin that enables them to manage diabetes better and more easily. Many focus on any regimen that lowers their risk of the life-altering complications of diabetes. For many, a device that manages their diabetes—like an artificial pancreas—is a great solution. That’s why the focus of JDRF’s research strategy spans across multiple therapeutic areas that will work towards curing, treating, and preventing T1D. The notion of “cure, treat, prevent” is a way of making certain that everyone with T1D and their families understands that JDRF’s research progress is focused on benefiting people at every stage of the disease.

We fund science aimed at delivering cures, at developing better treatments to serve as a “pathway to the cure”, and at stopping the disease before it takes hold in people with potential risk. Our strategic research plan has a mix of programs that will deliver a sustained stream of new life changing therapies in the near term, midterm and long term plan.

JDRF’s strategic research approach continues to deliver on our mission and our goal of turning type one into type none.

2013 key highlights and milestones - putting our research to the test

CURE

Encapsulation

Beta cell encapsulation has the potential to virtually eliminate the relentless daily management burden for those living with T1D: no need for multiple insulin injections or pump therapy, no more constant blood testing, and no more carb counting. People with T1D would just go about their lives for extended periods of time, up to 24 months, as if they didn’t even have the disease.

Encapsulation involves putting insulin-producing beta cells in a protective barrier and implanting them beneath the skin. These encapsulated beta cells will sense a person’s glucose levels and produce insulin as needed, while the barrier shields the cells from the body’s autoimmune attack that triggered the onset of T1D.

Encapsulation therapy overcomes two obstacles to earlier islet transplant procedures: a limited supply of donor islet cells and the need for continued immunosuppressive drugs to prevent the immune system from destroying
increase the likelihood of success. In early 2013, we formed the JDRF Encapsulation Consortium for leading scientists and researchers from 27 institutions to advance encapsulation in a collaborative, multidisciplinary forum.

JDRF investment has already helped bring one encapsulation product to early human testing, with several others heading to human trials in 2014. JDRF is partnering with biotechnology company ViaCyte to develop a first-of-its-kind encapsulation product that converts stem cells into immature pancreatic endocrine cells. The device maintained blood glucose at normal levels in diabetic mice.

JDRF supported a project conducted by Living Cell Technologies (LCT) involving the encapsulation of pig-derived islets for implantation into humans. LCT has conducted small human trials and is still compiling the results. Preliminary results show the product has had a positive effect on reducing dangerous low blood sugar events. JDRF is co-funding investigators at the Diabetes Research Institute (DRI) at the University of Miami. The team seeks to create a device that can provide the optimal environment for islets to survive and function for a long time. DRI hopes to take part of this device to human clinical trials in 2014. Preclinical encapsulation trials have been encouraging. JDRF continues to work on identifying the best materials for a permeable barrier and to work on the design of implanted devices to hold beta cells without being intrusive. While this research progresses, JDRF is already taking encapsulation out of the lab and into the real world.

Restoration
A full biological cure is the ultimate and permanent solution to all the complexity and problems of T1D. For a decade, JDRF has been exploring ways to restore the body’s ability to create new insulin-producing beta cells in the pancreas while preventing the autoimmune attack that triggers T1D. Together, these areas of investigation will eventually yield a permanent cure for T1D, and JDRF has made significant strides in both.

The JDRF Beta Cell Survival and Restoration Program is based on a simple principle: the body can heal itself. We believe the body can heal T1D as well, though it needs help from science to do so. Our research is focused on:

• expanding the number of beta cells so normal insulin production can resume.

Marla and Robert Oringer – Quebec Region

“We are motivated by JDRF’s advocacy leadership in advancing awareness and relentlessly pushing regulatory authorities to understand the importance and potential of technologies such as automated insulin delivery through closed-loop systems—known to most as the Artificial Pancreas program. JDRF’s efforts are catching the attention of the general public and drawing innovative outside groups to take an interest in diabetes.”
• extending the life and/or improving the health of underperforming beta cells; and
• delaying or preventing beta cell death.

A major focus in the program is to take existing drugs—approved for use for other conditions—and explore whether these drugs, alone or in combination with others, may have positive impact on either reducing beta cell stress and/or inducing beta cell survival. Another priority is to establish proof in human clinical studies that one or more of the repurposed drug candidates will indeed enhance beta cell survival and can be safely tolerated by patients. We’re also funding pioneering research to create new compounds and identify other molecules that might have a positive effect on beta cell health and restoration.

Identifying biomarkers, or indicators of disease progress and progression, is another key area that will facilitate early detection of subtle changes in beta cell health and function, giving us greater insight into beta cell stress and dysfunction.

Any effort to restore beta cells must also involve parallel efforts to tame the autoimmune attack. Successful restoration efforts must be combined with immune therapies that allow new and/or healthy beta cells to thrive and function normally. JDRF’s aggressive immunotherapy research program is developing therapies that promote tolerance to the beta cell autoantigens that trigger the attack on beta cells. Some of JDRF’s work in preventing T1D, particularly our exploration into an antigen-specific T1D vaccine, may also be applicable in the restoration field.

JDRF has set an ambitious goal to accomplish something never before done in biomedical research: reverse an autoimmune attack and restore the body to normal function. We are partnering with investigators, industry, and regulators so that we can advance a safe and effective therapy to people with T1D as soon as it is discovered.

TREAT

Artificial Pancreas

Currently, managing T1D is relentless. It requires people to constantly balance insulin delivery against the amount of food eaten, the amount of exercise, and even the stress of the workplace or school. Few people, regardless of age, can focus on this balancing act every moment of the day. But technology can.

Artificial pancreas (AP) systems will be the most revolutionary advance in diabetes care since the discovery of insulin. Like the body’s pancreas, AP systems will react to rising blood-glucose levels by combining monitoring technology with insulin pumps to provide the right amount of insulin at the right time. Not only will AP systems result in much tighter control, lowering the risk of health complications later in life, they will also reduce the constant worry about blood-sugar levels and what must be done to manage them.

In less than a decade, JDRF has transformed the AP field. The JDRF Artificial Pancreas Consortium—which brings the best researchers in the T1D field together with some of the world’s leading engineers and mathematicians—has driven virtually every major advance in the AP field. Until we stepped in, companies and others were not heavily committed to developing this kind of device. The six-step roadmap JDRF laid out to create successively more sophisticated versions of the AP has since been embraced by manufacturers to guide their own R&D programs.

A first-generation system—operating low-glucose suspend technology, which will partially automate glucose control—was recently completed by Medtronic and approved by the U.S. Food and Drug Administration (FDA). JDRF is already driving progress forward on more sophisticated algorithms and improved glucose sensors so that we can achieve second- and third-generation devices. Treat-to-range devices will predict high and low blood-glucose levels and adjust insulin dosing accordingly to maintain blood glucose within a set range. Treat-to-target devices will be designed to maintain blood glucose not just within a range but at a target level. Eventually, we envision a fully automated, multi hormonal, dual-chamber artificial pancreas system capable of keeping blood sugar at specific levels and of delivering, in addition to insulin, key pancreatic hormones that influence blood-glucose levels.

It is no exaggeration to say that without JDRF’s leadership we would still be years away from seeing AP systems in the hands of people with T1D. In addition to the research, JDRF’s advocacy arm worked closely with the FDA to develop regulatory guidance to help ensure that AP devices could move quickly to human clinical trials. Today, those trials are under way, and early results show they work.

Smart Insulin

Eliminating virtually all of the daily burdens associated with mechanically managing T1D would profoundly enhance and simplify the lives of people with the disease. Moreover, by improving overall blood-glucose controls, the risks of life-threatening complications would sharply diminish, leading to longer, healthier lives. Smart insulin is a drug designed to ensure perfect glucose control throughout any given day by turning on when it is needed and off when it is not—liberating people with T1D from multiple daily insulin injections and the constant monitoring that accompanies the disease.

Smart insulin is glucose-responsive insulin—inulin in a form that renders it essentially inert until it is needed. A person with T1D would take a shot, or a pill, of this insulin—enough to cover the needs of a day—and the insulin would circulate in the body until blood-glucose levels start to rise. As glucose rises, the binding element of the insulin releases the insulin so it is free to do its job. As glucose levels return to normal, the release of insulin stops until it is needed again. Smart insulin would automatically activate or deactivate in response to the glucose in the blood, thus giving tighter...
control essentially as if the beta cells were working normally.

Over the last decade, JDRF has been a leader in the smart insulin field. It was our early support of the company Smart Cells, Inc. at its riskiest stage that sustained the idea and validated the initial concept. And after this proof that smart insulin is a potential T1D therapy, industry partners have made a financial commitment to take the concept further along the development pipeline. Beyond its support of Smart Cells, JDRF has continued to provide leadership, most recently through the Grand Challenge Prize to stimulate the generation of novel ideas from a diverse array of disciplines to advance development of smart insulin.

Phase 1 of the challenge awarded prizes to three research projects in 2011 for their initial ideas on delivery and overdose prevention. Phase 2 will be the discovery phase, building on the winning ideas in Phase 1. This phase will provide experimental design and validation of potential smart insulin drugs, culminating in pre-clinical proof of principal studies in animal models. The final phase of the challenge will take the most promising drugs to human clinical trials.

While still years away from becoming a treatment, smart insulin will, with continued JDRF investment, become another life-changing therapy for those with T1D.

**PREVENT**

**Prevention**

Preventing T1D from ever developing in anyone is the ultimate answer. Consider polio or smallpox—neither has been cured, but effective vaccines have largely eradicated these diseases. JDRF is pursuing both primary and secondary prevention strategies. Primary prevention means preventing the autoimmune attack so people never develop T1D at all. Secondary prevention focuses on finding ways to prevent insulin dependence in individuals at risk or where the autoimmune attack on beta cells has already begun.

We know that the largest risk factor for T1D is genetics. In fact, as a result of research funded by JDRF and the National Institutes of Health (NIH), we’ve now identified more than 50 genes that confer risk for T1D. We understand T1D genetics better than we did only a decade ago, and we have identified auto antibodies associated with the disease so we can more successfully screen those at risk.

But genes alone do not cause the disease, and scientists are now halfway through a longitudinal study called TEDDY (The Environmental Determinants of Diabetes in the Young) to identify the environmental factors that may trigger it. The study, funded by the NIH’s Special Diabetes Program, a program in existence thanks in part to JDRF’s advocacy efforts, is exploring whether factors such as antibiotics, viruses, gut microbes, cow’s milk, and/or deficiency of vitamin D or omega-3s are culprits in the onset of T1D.

Zeroing in on the causes of T1D is fundamental to devising approaches to prevent the onset of the disease. With our expanding knowledge, JDRF has intensified investigation into potential vaccines to prevent T1D. JDRF is pioneering research into such vaccines, which might be used either before autoimmunity starts or after it starts but before total insulin dependence—or, ideally, a universal childhood vaccine to prevent T1D, much like vaccines we administer to children to prevent measles, chicken pox, and other conditions.

JDRF is funding considerable research in other prevention strategies as well, including:

- The use of anti-inflammatory agents and other therapies to delay and prevent insulin dependence
- An approach that shows promise in suppressing the autoimmune response triggering T1D without compromising the overall immune system’s ability to fight back
- A Phase II clinical trial studying whether orally delivered insulin can prevent T1D onset in children at high risk
- A trial examining whether nasally delivered insulin can prevent T1D onset where the autoimmune attack has already begun
Our research is ambitious, but so is our goal—to ensure that no one ever again needs to worry about being diagnosed with TID.

**COMPPLICATIONS**

Despite significant advances in blood-glucose monitoring and insulin therapy, people with TID still have to worry about the damaging effects of high blood-glucose levels, which can lead to life-threatening complications. JDRF is pursuing multiple strategies to resist and reverse conditions such as diabetic retinopathy (eye disease), diabetic nephropathy (kidney disease), and nerve damage. By supporting extensive studies and creating a platform for widespread collaboration, we are striving to better identify ways to predict, prevent, and treat these devastating complications.

The Joslin 50-Year Medalist Study is working to identify factors that may confer resistance or susceptibility to diabetic complications. The JDRF-supported study, which began in 1970, is constantly revealing new information about the long-term effects of TID in people who have lived with the disease for 50 years or longer without developing complications. Findings from the study are being used to further drug-discovery and measurement tools to predict risk or stage the progression of complications.

Since approximately one-third of people with TID develop diabetic nephropathy, JDRF formed the largest-ever international effort to investigate the genetics of kidney disease. The JDRF Genetics of Diabetic Nephropathy Collaborative Research Initiative is a three-year, $7-million initiative that brings together top scientists to expand previous research and share findings in an effort to identify possible ways to prevent and treat this life-threatening condition. The three initial key activities of the collaborative project include looking for genes that differ between people with TID who do and do not have diabetic nephropathy; identifying genes that predict how quickly a person with TID may develop kidney failure; and identifying genes that predict rapid progression of decline in kidney function.

Research on new therapies for all stages of diabetic eye disease—the leading cause of blindness in working-age adults—continues through our Healthy Eye Project. The project is focused on two main areas: understanding why some people with TID, even those who have lived with the disease for a long time, do not develop diabetic eye disease, as well as why some people respond to drug treatment while others do not; and clinical trials to identify and test molecular targets that improve the stability of blood vessels in the eye and/or address other risk factors for diabetic retinopathy. The findings are adding greatly to our understanding of the condition and may lead to new mechanism-based therapies to prevent, treat, and reverse diabetic eye disease.

Ending and preventing diabetic complications is essential to JDRF—and our research in this field has the potential to greatly improve quality of life for millions of people living with TID.
JDRF is uniquely positioned to create a future without type 1 diabetes (T1D), and our JDRF Canadian Clinical Trial Network (JDRF CCTN) is funding groundbreaking and innovative research that holds significant promise for turning type one into type none.

Now in the fourth year of our partnership with the Government of Canada, JDRF CCTN continues to drive progress, from advances in the lab to therapies that positively impact everyone living with T1D. Born of a $20 million commitment from the Federal Government, a $13.9 million commitment from JDRF, and most recently a $3 million contribution from the WB Family Foundation, this $33.9 million investment is bringing life-changing therapies out of the lab and into real life.

Since March 2011, JDRF CCTN has successfully launched nine clinical trials and two technology projects. Included among these are five potentially life-changing Artificial Pancreas-related trials, two more than our initial goal of three such studies. The Artificial Pancreas is a huge breakthrough in treatment technology, with the potential to automate detection of blood sugar levels and deliver insulin accordingly, eliminating multiple insulin injections and finger pricks. This amazing advancement has the power to transform the lives of those living with T1D.

This is just one example of the incredible research currently underway, thanks to the CCTN.

How the West was won: Competing for a Cure
The WB Family Foundation’s recent $3 million contribution has been a game-changer for Canadian T1D research.

Following this gift, a research competition was held in 2013 to select the most promising projects aimed at finding a cure for T1D. The competition opened the door to an expansion of the Network into western Canada, where these funds will support new clinical trials and studies. This move westward is expediting meaningful scientific progress by funding three new trials specifically in the cure therapeutic area.

New hope for a New Year
In 2013, JDRF CCTN clinical trials were centered in Ontario, with hubs in London, Ottawa, and Toronto. Institutions continuing to participate include: Lawson Health Research Institute and Western University in London; the Children’s Hospital of Eastern Ontario and The Ottawa Hospital in Ottawa; and The Hospital for Sick Children (SickKids), Mount Sinai Hospital, and the University Health Network in Toronto.

In 2014, with the Network’s new presence in the west, JDRF CCTN’s partnering institutions are moving research forward to expedite and sustain meaningful scientific progress that will improve lives today and lead to a cure tomorrow.

Over the course of the coming year, we will continue enrolling patients and providing information about the trials as they open to the public. Our plan ensures there will be an ongoing stream of life-changing therapies moving from development through to commercialization that ease the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D. Together, we will turn type one into type none. For more information, please visit jdrf.ca/cctn.
2013 CANADIAN HIGHLIGHTS AND MILESTONES

JDRF CCTN trials offer an opportunity to become involved in research

The JDRF Artificial Pancreas Program (APP) is a coordinated and collaborative global effort to concentrate and focus resources on developing so-called ‘closed loop’ systems that connect information from continuous glucose sensors with insulin pumps to optimize control of blood sugar. JDRF CCTN is implementing studies that provide an optimized clinical platform that provides the benefits of research to Canada, and also helps advance the global APP effort.

Preventing hypoglycemia

JDRF CCTN researchers are participating in trials that are testing the ability of AP programs to suspend delivery of insulin to prevent night-time hypoglycemia. These trials, in adults and in children, are ongoing in Canada and in collaboration with American researchers at Stanford. There has been enormous interest among Canadians with T1D in participating in these studies.

Helping people with T1D during the transition from adolescent to adult care

It has been observed that a significant proportion of adolescents with T1D do not adhere to their treatment regimen, especially in the first year of transition to adult medical care. Canadian data shows that in the first year of transition 41% of T1D patients drop out of adult medical care and 46% report difficulties with the transition process. JDRF CCTN is testing the effect of a structured transition clinic on overall management of diabetes, reduction of acute complications and hospitalizations, and quality of life in adolescents and young adults with T1D.

Preventing Complications

Despite significant advances in blood-glucose monitoring and insulin therapy, people with T1D still need to be cognizant of the damaging effects of high blood-glucose levels, which can lead to life-threatening complications. JDRF is pursuing multiple strategies to resist and reverse conditions such as diabetic retinopathy (eye disease), diabetic nephropathy (kidney disease), and nerve damage. JDRF CCTN trials are part of the overall effort to prevent the development of complications.

Long-term diabetes without complications

JDRF-funded investigators have now begun the identification of a similar cohort of Canadians who have had long-term T1D protected from complications. Findings from both cohorts will be used to further drug-discovery and measurement tools to predict risk or stage the progression of complications.

JDRF is partnering with biotechnology company ViaCyte to develop a first-of-its-kind encapsulation product that converts stem cells into immature pancreatic endocrine cells. The device maintained blood glucose at normal levels in diabetic mice.

Pre-clinical studies of a novel procedure and encapsulation device are being performed by JDRF Canadian Clinical Trial Network (JDRF CCTN) researchers at the University of British Columbia. Working in JDRF’s Encapsulation Consortium, and with support from JDRF CCTN, they will test these cells in a novel encapsulation device.

Canadian investigators from the University of British Columbia are planning to test a drug approved for another autoimmune disease in T1D. This pilot trial, which will be conducted by the JDRF CCTN, utilizes our understanding of the mechanism of autoimmune destruction to intervene in the process. The hope is that deploying this drug helps preserve beta cells, and may someday prevent the development of T1D.

Continuous Glucose Monitoring (CGM)

JDRF-sponsored research has demonstrated the cost-effectiveness of continuous glucose monitoring (CGM) compared to standard glucose monitoring. The effectiveness of implementing CGM in children and adolescents is still not clear. JDRF CCTN is testing the hypothesis that initiating CGM at the same time as pump therapy could improve outcomes compared to delaying CGM introductions by 6 months.

Presently, there are no open standards for communication between diabetes devices (insulin pumps, blood glucose meters and continuous glucose monitors). JDRF CCTN investigators are now working on a project to bring industry together on the development and demonstration of open standards for communication among diabetes devices.
<table>
<thead>
<tr>
<th>Researcher</th>
<th>Trials</th>
<th>Province</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Joseph A Cafazzo, Ph.D. P.Eng.</td>
<td>Artificial Pancreas Standards and Technical Platform Project</td>
<td>ON</td>
</tr>
<tr>
<td>Cheril Clarson, M.D.</td>
<td>Structured transition from pediatric care to adult care in type 1 diabetes</td>
<td>ON</td>
</tr>
<tr>
<td>Denice Feig, M.D.</td>
<td>Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy Trial</td>
<td>ON</td>
</tr>
<tr>
<td>Stewart Harris, M.D.</td>
<td>A Strategy to Improve the Care &amp; Outcome of Diabetes in On-Reserve Pregnant First Nations Women</td>
<td>ON</td>
</tr>
<tr>
<td>Irene Hramiak, M.D.</td>
<td>Feasibility Assessment of Prototype Nocturnal Hypoglycemia Reduction System</td>
<td>ON</td>
</tr>
<tr>
<td>Irene Hramiak, M.D.</td>
<td>Reducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes</td>
<td>ON</td>
</tr>
<tr>
<td>Timothy Kieffer, Ph.D.</td>
<td>Treatment of Diabetes with Stem Cell Derived Islets (NEW)</td>
<td>BC</td>
</tr>
<tr>
<td>Margaret Lawson, M.D.</td>
<td>Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes</td>
<td>ON</td>
</tr>
<tr>
<td>Farid Mahmud, M.D.</td>
<td>Celiac disease &amp; Diabetes - Dietary Intervention &amp; Evaluation Trial: a RCT to evaluate the efficacy and safety of a gluten-free diet in patients with asymptomatic Celiac disease &amp; T1D</td>
<td>ON</td>
</tr>
<tr>
<td>Farid Mahmud, M.D.</td>
<td>Expansion of the “Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial” in Canada</td>
<td>ON</td>
</tr>
<tr>
<td>Bruce Perkins, M.D.</td>
<td>Pilot for semi-automated computerized overnight basal rate assessment protocol</td>
<td>ON</td>
</tr>
<tr>
<td>Rusung Tan, M.D., Ph.D.</td>
<td>Clinical Trial of Ustekinumab to Prevent Type 1 Diabetes (NEW)</td>
<td>BC</td>
</tr>
</tbody>
</table>
Medtronic of Canada Ltd. has been a committed partner of JDRF for over a decade. In 2013, Medtronic graciously provided sponsorship for JDRF’s T1D Insider newsletter, Galas, and was a National sponsor for the Diabetes Research Symposiums, and participated and had booths at the TELUS Walk to Cure Diabetes locations across Canada. Medtronic is proud to be involved in JDRF’s CCTN clinical trials as a diabetes technology partner. To date, Medtronic has provided more than $850,000 to JDRF Canada in sponsorship and in-kind contributions and has worked closely with the JDRF to improve access to diabetes technology in Canada to help improve the lives of people living with diabetes. For more information please visit www.medtronicdiabetes.ca.

Sun Life Financial has a longstanding relationship with JDRF that grows stronger each year. Employees across the country have been inspired to get involved, with many of them sitting on committees for the TELUS Walk to Cure Diabetes and Ride for Diabetes Research, and still more participating in both fundraising events. In addition to these core programs, in 2013 Sun Life partnered with the CFL to contribute more than $40,000 through the Kick Diabetes Program. T1D families also got to participate in the Sun Life Financial Skate with the Leafs at the Air Canada Centre, and were able to enjoy donated Community Suites at Toronto Raptors games. JDRF is thrilled to welcome Sun Life Financial as a National sponsor of the TELUS Walk to Cure Diabetes in 2014. For more information please visit sunlife.ca.

Over the years, Eli Lilly Canada has been a tremendous supporter of JDRF. Lilly employees continually demonstrate a commitment to fundraising and great team spirit through their participation in a variety of initiatives, including the TELUS Walk to Cure Diabetes. In 2013, Lilly supported our Diabetes Awareness Month campaign through an educational advertorial published in The Globe and Mail. Lilly also created a cause-related marketing program, with a portion of its proceeds going to JDRF. An additional $100,000 donation was provided to establish a fellowship program, enabling JDRF to provide funding for two research fellows. To date, Lilly has generously given over $400,000 to JDRF in support of diabetes research. For more information please visit lilly.ca.

Corporate Partners

JDRF is privileged to have many passionate and generous corporate partners whose valuable support helps us keep people with type 1 diabetes (T1D) healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D. This year, we would like to recognize the following dedicated companies for their support:

Stock Family - Lianne & Jay – South Central Ontario Region

“Without a doubt, our son Noah is our motivation to support JDRF. As parents, all we can do is show our support, and raise awareness and money for research – for him and everyone else living with type 1 diabetes, and children down the road.”
Join the Community! Each year the TELUS Walk to Cure Diabetes brings together Canadians from communities across the country for an outdoor celebration. This signature fundraising event raises funds and awareness to make a difference in the lives of over 300,000 Canadians living with type 1 diabetes (T1D). The fun and energetic event is a growing national movement to cure T1D, and each year continues to attract new community partners and participants.

The Walk is JDRF’s largest annual fundraising program bringing together more than 45,000 participants who raise funds supporting research to cure, better treat, and prevent T1D. In 2013, the TELUS Walk to Cure Diabetes was held in more than 70 communities across the country, raising almost $7.7 million. This success is because of the incredible efforts of our participants, sponsors, and volunteers. JDRF cannot express how appreciative we are for the endless dedication and generosity of our supporters!

Corporate Sponsor Support

“Our TELUS team is committed to a simple philosophy – we give where we live. This is just one reason why we have been the title sponsor of the TELUS Walk to Cure Diabetes since 2008 and renewed our partnership with JDRF for another three years. Through this partnership, we provide our technology expertise and fund Canadian-based research programs that improve the lives of those affected by juvenile (Type 1) diabetes,” said Paul Lepage, President of TELUS Health and National Co-Chair of the 2014 TELUS Walk to Cure Diabetes. “In 2013, more than 4,000 TELUS team members and their friends and families demonstrated our philosophy by participating in Walks to Cure Diabetes from St. John’s to Victoria, raising more than $540,000. By 2015, we expect corporate and employee contributions to JDRF to total more than $10 million.”

As the national title sponsor, TELUS has contributed more than $7 million to JDRF through corporate donations and employee fundraising since our partnership began in 2000.

JDRF also values the generous support of national sponsors Sun Life Financial (new in 2014) and Best Days, brought to you by ONETOUCH, who has contributed over $1 million to JDRF since 1990 through galas, corporate matches, sponsorship and employee fundraising, as well as our national supplier SunRype Products, who has contributed almost $800,000 in support to JDRF.

Thank you to all our sponsors, volunteers, and participants for continuing to amaze us with their incredible support and fundraising efforts! Their contributions are instrumental in the success of the TELUS Walk to Cure Diabetes. We look forward to another successful year in 2014!
Every year, the JDRF Ride for Diabetes Research continues to increase in popularity. In 2013, more than 22,000 people participated at 22 sites across the country. Unitig corporate Canada, this high-energy stationary ride encourages a friendly competition to see who can show the most team spirit and raise the most funds for type 1 diabetes (T1D) research.

JDRF is excited to announce the 2013 Ride program raised $6.8 million. Each year, the success of the Ride is a direct result of the hard work and enthusiasm of JDRF volunteers and staff.

“The key ingredients that make the Ride so successful are the friendly competition among the teams and corporations, the fact that it is a great team building opportunity adding to corporate spirit, and quite simply it is a lot of fun. These elements ensure that riders, and companies, return year after year to enjoy the infectious enthusiasm of the JDRF Ride. My personal favourite memory of the Ride was the pride I had looking over a sea of riders, laughing and responding to the music, and noticing the waves of corporate colors participating. It was unforgettable!”

- JP Savage, National Chair, JDRF Ride for Diabetes Research

“I Ride for my son, David. David was diagnosed with type 1 diabetes when he was five. Now that he’s 30 and I reflect on the past quarter of a century, I am astonished at the incredible progress that has been made. The JDRF Ride is an amazing, high energy, corporate fundraising event that contributes significantly to JDRF’s unwavering commitment to helping type 1 diabetics live healthier, easier, and safer lives. Come join us…. be part of the team that finds the cure!”

- Lorn, Ride Participant

The 2013 Ride Program featured celebrity athletes who came out to join teams as honourary members and for the second year we saw Scotiabank surpass the $1 million level in funds raised. In total, 360 companies put the JDRF Ride on their calendars and engaged employees to participate.

We would like to thank our corporate leaders, participants and volunteers across Canada whose dedicated efforts contributed to the success of the 2013 JDRF Ride campaign. As we move ahead to the 2014 season, we are focused on taking the Ride to new heights and look forward to your continued support. For more information please visit jdrf.ca/ride.
GALAS
JDRF galas represent a core fundraising program for the Foundation. In 2013, more than 3,400 people attended galas in 10 cities nationwide raising over $3.5 million.

Each gala across the country has a unique theme for their evening celebration. Chosen with the help of JDRF Chapters and their gala Committees, themes in 2013 included: Gatsby Glamour (Kelowna), The Latino Festival (Nanaimo), Moonlight Magic (Victoria), Motown Groove (Vancouver), Denim and Diamonds (Edmonton), The Sky’s the Limit (Calgary), Starry Starry Night (Winnipeg), Starlight Soiree Gatsby Magic (Mississauga), Passion Ball (Toronto) and Dia-Beat-It (Montreal).

Regardless of the theme, guests enjoy an elegant evening of fine dining, entertainment, dancing, silent and live auctions and JDRF’s signature Fund A Cure.

JDRF’s Fund A Cure is always a highlight providing guests with the opportunity to donate the gift level of their choice and receive a Fund A Cure Bear, in addition to a tax receipt for their contribution.

Thank you to the many volunteers and supporters for your valuable time, generosity, and for making these exceptional fundraising evenings possible. For more information visit jdrf.ca/galas.
OUTREACH

JDRF’s Outreach Program, established in 2006, operates nationally through all JDRF Chapters and continues to evolve as it updates and introduces new initiatives. As a Foundation, we understand the importance of providing social, emotional, and practical support and information for all ages and stages of T1D.

Adult Toolkits
After receiving many requests, JDRF began producing a toolkit that would provide useful information to adults living with T1D – both newly diagnosed or those that have been living with T1D for a number of years. Since its introduction in 2012, the reaction to this resource has been very well received. To download the Adult Type 1 Toolkit visit jdrf.ca/adultswitht1d.

Bag of Hope
The Bag of Hope, sponsored by Roche (Accu-Chek®), contains a selection of reference and educational materials. Once an individual receives a Bag of Hope they become part of JDRF’s Family Network. Since 2008, when the program was introduced, JDRF has connected with over 3,200 families. Many of these families have become involved with the Foundation through the mentoring program, or as volunteers or participants in our core fundraising programs. To request a Bag of Hope visit jdrf.ca/newlydiagnosed.

Outreach Volunteer Network
The Outreach Program is strengthened by the dedication and commitment of the National Outreach Committee. The Outreach Volunteer Network, led by Janice Hicks, National Outreach Chair, is a group of volunteers who communicate quarterly and provide national updates on programs, share best practices, brainstorm new concepts, and overcome any challenges.

School Advisory Toolkit
The School Advisory Toolkit, generously supported by LifeScan Canada (OneTouch®), provides information for parents as a tool to assist them in communicating and educating their child’s school about T1D. To download the School Advisory Toolkit visit jdrf.ca/schoolkit.

Stephen Emery – North Eastern Ontario Region
“When Maya was diagnosed a physician told us this is one of the diseases they can cure, they just need time and money. I am driven to raise awareness and money for research. We’ve had the privilege of experiencing JDRF research first hand. I am committed to do whatever I can to find a cure... Not having a cure is unacceptable.”
DIABETES RESEARCH SYMPOSIUMS

JDRF is committed to developing life-changing therapies, moving from development through to commercialization, that lessen the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D. Each year JDRF shares the latest research updates from JDRF-funded researchers and partners, and motivational stories from speakers living with T1D at their Diabetes Research Symposiums. In 2013, JDRF held Diabetes Research Symposiums in 13 cities across Canada. If you are interested in hearing the latest updates on JDRF-funded research, contact your local JDRF Chapter to attend the next Diabetes Research Symposium near you. JDRF is grateful to our national sponsors - Bayer, GlaxoSmithKline (GSK), and Medtronic - for their generous support of these events.

“Aquilini Group – Vancouver

“We proudly support JDRF, one of our core charities, through the Rockin’ for Research gala and Ride for Diabetes Research. All levels of our company, from ownership to staff, work together to increase awareness of T1D and raise much-needed funds for research. We’re inspired by the courage of those living with T1D and look forward to the day when there’s a cure.”
**Government Relations**

**Grassroots Advocacy Program**
The Grassroots Advocacy program is a platform that brings together people who are dedicated to making a difference in the lives of all individuals touched by type 1 diabetes (T1D). Across Canada, more than 3,300 JDRF advocates are working together to make their voices heard in the federal and provincial governments by participating in online letter writing campaigns, developing long-lasting relationships with their Members of Parliament, and raising invaluable awareness for T1D. These relationships strengthen our community, provide support for those living with diabetes, and strengthen the voice of JDRF in delivering our message to the government - the need for a cure and the need to accelerate the pace of research through funding from our federal government.

**Diabetes Insulin Pump Program**
JDRF has been actively working with families across Canada to seek commitment from provincial governments to provide insulin pump coverage to all individuals living with T1D. In March 2013, the Government of Alberta announced insulin pump coverage to eligible residents of all ages, and, in April 2013, the Government Nova Scotia announced insulin pump coverage for residents aged 18 or younger and coverage for pump supplies for young adults aged 19 to 25 years old. Our goal is to influence all provinces across the country to ensure that one day all Canadians, regardless of their age, will have access to a Diabetes Insulin Pump Program.
JDRF 2013 International Children’s Congress

T1D is a global problem requiring a united effort. In July 2013, over 150 delegates from across the U.S and around the world congregated in Washington, D.C. for the JDRF 2013 Children’s Congress to urge lawmakers to continue funding T1D research. Megan Beamish, age 14, represented Canada as one of six delegates from around the world selected to participate in this unique and empowering opportunity to help Members of Congress understand what life with T1D is like and why research to find the cure for diabetes and its complications is so critical.

2014 Kids for a Cure Lobby Day

In November 2014, JDRF is planning the Kids for a Cure Lobby Day in Ottawa, an event that provides children living with T1D with the opportunity to meet with Members of Parliament to increase awareness about T1D, discuss the challenges they face living with T1D and the importance of expanding the JDRF Canadian Clinical Trial Network (JDRF CCTN) across Canada.
When it comes to diabetes management, it’s all about the numbers. There can be power in numbers, especially with each person who joins the fight against type 1 diabetes (T1D). The theme for National Diabetes Awareness Month (NDAM) 2013 was “Diabetes by Numbers: We’re All Counting on You!” We witnessed the power and strength of numbers first-hand during NDAM and on World Diabetes Day (WDD) on November 14.

NDAM, celebrated internationally every November, helps raise awareness of all forms of diabetes, its signs and symptoms, and gains support for critical research toward preventing, better treating and curing all forms of the disease. In 2013, JDRF invited people to showcase Canadian Diabetes Champions in the fight against diabetes by sharing their stories through Facebook (JDRFCanada) and Twitter (@JDRF_Canada). We also encouraged people to share stories with JDRF Canada on Facebook about how they are taking charge of their diabetes, highlighting their bravery while emphasizing the importance of standing together to fight the disease and find a cure. For the sixth year, JDRF also invited youth aged 10 and older to submit a video to our Annual JDRF Youth Video Contest focused on the Diabetes by Numbers theme. The deadline for submissions was March 31, 2014. The winning entry for the 6th Annual JDRF Youth Video Contest was submitted by 11 year old Cole Byers.

Claude and Bonny Chapman – Winnipeg

“Our son Chris, who is now 38, was diagnosed at age 13 with type 1 diabetes. Chris is also intellectually challenged, which is something else we manage daily. Chris is now dealing with eye complications that continue to threaten his quality of life. Our goal is to help find a cure so that children and families never have to experience any of the lows that come along with diabetes. We are continuously motivated to reach our goal because of the passion and commitment from staff, volunteers and other parents who we have connected with in our Starry Starry Night Gala activities.” – Claude Chapman

“I see JDRF as a realistic route to finding the cure for diabetes because it funds diverse areas of research for type 1 diabetes, which leads to exciting research that gives hope to families like ours. JDRF is working not only to find a cure for diabetes, but to find treatments for its complications and develop devices that will improve the quality of life of people living with T1D. The Winnipeg chapter has hard-working, dedicated and passionate staff that not only inspires participation, but also works with families to provide peer support to the children and families dealing with T1D.” – Bonny Chapman

JDRF would like to thank our sponsor Lilly, supported by the Lilly Giving Program from Eli Lilly Canada Inc., for their valuable contribution and support with NDAM and WDD. We would also like to thank all our families, friends, staff and the individuals who shared their stories with us on Facebook and Twitter for making NDAM and WDD such a success! Together, as a team and community, we will turn type one into type none.
Our Partners

With the dedication and support of our national partners, JDRF can continue to move forward and aggressively work towards **turning type one into type none** faster. Your contributions help accelerate progress down the path to improving lives. We are proud to partner with the following organizations and want to thank each of them for their commitment and dedication to JDRF.
Ross Mikkelsen, Barbecues Galore – Calgary

“JDRF has been near and dear to my heart ever since my daughter was diagnosed with type 1 diabetes. I support JDRF because it is an organization that has one clear goal - to cure type 1 diabetes. When you support JDRF, you know where your money is going and what it is supporting. Through its different research initiatives, supporters of JDRF can rest assured that their money is being used to find a cure for T1D.”
Karen and Ryan Shay and Family
Silpada Designs Canada
Transamerica Life Canada
Rhoda and Robert Vineberg
Debra and Dr. Sidney Zucker
1 Anonymous

Gift Amount $50,000 - $99,999
ACME United Limited
Geoff Beattie
J. Armand Bombardier Foundation
Brawn Family Foundation
Brian Randall Charity Golf Classic
Fondation Martin Brodeur
Janet and Tye Burt
Cadillac Fairview Corporation Limited
CanadaHelps.org
Don Chamberlain
Joanne and Douglas Cohen
Collumbin Family Fund at the Toronto Community Foundation
CPI Canada
Crew Energy Inc.
Michael Cruickshank
CTVglobemedia Montreal
Eagle Pointe Lodge & Shaw Communications
Penny and Gordon Echenberg Family Foundation
The Economical Insurance Group
Isabel and Wayne Fox
The Frost Family
GMP Securities
Hatch
Brian and Valerie Harris
Lynn and Robert Hewett
Stephen Kaplan Family Foundation
Karen and Lorne Kutner
Susan and John Leach
Queenie Leibel
Tamara and Justin MacCormack
The McKee Family
Sue and Murray Mason
Shelly and Alan Norris
Annette Oelbaum and Family - In Memory of Ronald Oelbaum
Maureen and Peter Oliver
PH Restaurants Limited Partnership
The Poppleton Family
Protech Chemicals Ltd.
Regina JDRF Charity Golf Tournament
Rotating Right Inc.
RPM Technologies Corporation
SGL Canada
Shaw Communications
Sobeys Inc.
The Stroebele Family
Mrs. Myrna and Dr. Noah Weiszn er
2 Anonymous

Gift Amount $25,000 - $49,999
The Abercrombie Foundation
Alberta Culture and Community Spirit
Ian & Kim Anderson
Astral Media
ATCO Energy Solutions
Auto Control Medical Inc.
The Bagg Family Fundraisers; Spring Fling; Cuisine for a Cure; Swim for a Cure
Bank of America Merrill Lynch
The Barrie Advance
Bayshore Capital Inc.
Barbecues Galore
Bell Media
Blue Bell Social Club
Scott Bolton
Guiseppe and Elina Borsellino
Brian Randall Charity Golf Classic
The Bridle Bash Foundation
Martin Cairns
Caisse de bienfaisance des employés et retraités du CN
Calgary Herald
Canaccord Wealth Management
Canada Safeway Ltd.
Capital One
Children’s Books for Charity
The Mary and Gordon Christopher Foundation
CN Employees’ and Pensioners’ Community Fund
Compass Group Canada
Conam Charitable Foundation
The Conservatory Group
Corby Distilleries Limited
Cormark Securities Inc.
CTV Atlantic
Kristin and Ashit Dattani
DC Bank
Dinner with the Chiefs - Peel Regional Police
Edmonton Community Foundation
John and Barbara Feick
Fifty 50 Foods LP
Janice and Kenneth Finkelstein
Gail and Jimmy Garfinkle
The Georgia Straight
Global Edmonton
Global Toronto
Grant Family Golf Tournament
George Grossman
Stephen Haipper
Claire and Bryan Haynes
Hyatt Regency Vancouver
Investments Monsap Inc.
Tara Jacquot
JC Clark Ltd.
Jewish Community Foundation of Montreal
The Keenan Foundation
Evelyn and David Kozloff
Susanne and Gary Lang
Longo’s
Heather and Ron Miller and Family
Giuseppe Monticciolo
Robert and Melanie Nearing and Family
Oliver & Bonacini Restaurants
Lois and Tim O’Neil
The Pepsi Bottling Group
Greg Perkell
Piller’s

Gift Amount $10,000 - $24,999
A Concert for the Kids
A.B.C. Recycling Ltd.
Alberta and Northwest Territories Regional Council of Carpenters and Allied Workers
All Hockey International Ball Hockey Tournament
Alliance Legal Services
Sam Alter
Altus Group
The Aquilini Family
Barbara J. and Robert C. Armstrong
Athol Murray College of Notre Dame
ATI Telecom Intl. Company
Atlantic Provinces Trucking Association
Avison Young Commercial Real Estate
Aviva Canada
Mary Ann Azzarello
Cottonwood Shots For Kids
Robert H. Cowan
Craig-Casgrain Fund of Tides Canada Foundation
CRM Dynamics
Crowne Plaza Moncton
Cushman & Wakefield
CYCLE 4 What Matters Foundation
D & H Ltd.
Dads Golf Tournament
Stacey and Stuart Dalgleish
Dance 4 Diabetes – Hannah Hempinstall
Davies, Ward, Phillips & Vineberg LLP
Demtra Sheet Metal Industries Ltd.
Mary Jane Devine and Mike Cyr
Dany Di Schavi
Diabetes Express
Roy Dias
Direct Cash Payments Inc.
Dr. Alfred E. Deacon Medical Research Foundation Inc.
Duca Financial Services
Dundee Wealth Management
Eldon & Anne Foote Foundation
Electri-Tech Services Inc.
EnCana Corporation
Esdale Printing Company
Father Michael Luchka Memorial Charity Golf Tournament - Knights of Columbus
David Feldman
Ronald Ferguson
Fidelity Investments Canada Limited
Margot and Brian Fitzpatrick
Founders Cup Charity Foundation
Alan Friedman
FundSERV
Wally Gabler and Carol Cushing
Ramona & Ed Gallos - Master Roofing Ltd.
The Garfinkle Family
Gary Bluestein Charitable Foundation
Genworth Financial Canada
Global BC
Global Regina
Gluskin Sheff & Associates Inc.
Ira Gluskin
GM Sernas & Associates Ltd. Employee Charitable Trust Fund
Goldman Sachs Canada Inc.
Goodmans LLP
Dr. Yves Gosselin
Graoch Associates
Grayross Foundation
Groupe Petra
Fran and Doug Grundman
Bill Gula
H&R Reit
Mak Hakim
Harry Winston Diamond Corporation
Harvard Broadcasting
Highrise Window Technologies Inc.
Mrs. Rita and Dr. Wayne Hildahl
HomeLife Realty Golf to the Cure
Angela Homer and Prentice Lee
Honda Canada
Hydro Québec
Imperial Capital
Independent Order Of Foresters Branch
Cindy Innes and the late Drew Innes
Instl Equity Childrens Charities
IrvineScheinHockey Tournament
Ivanhoе Cambridge Inc.
IWK Community Grants Program
Jammin’ for JD
JD Sweid Foods
Journeys with Heart - Turquoise Turkey Tour
JP Morgan Securities Canada Inc.
K + S Potash
Yvonne Kala
Kelsey’s For Kids
Jeffrey Kerbel
Timothy Kerr Foundation
Warren Kimel
King’s Head Pub
Kingway Foundation
Kiwanis Club of Casa Loma
Debbie and Danny Kornhauser
Marilena and Michael Latifi
Lawton’s Drugs
Bruce Leboff
Bill and Sharon LeClair
Les Placements Antis. Inc.
Carol Lezack - Walmart
Lindvest Properties Limited
LK Promotions and Advertising
Loyola Student House of Assembly
Isabelle and Michael MacBean
Major League Soccer LLC
Manitoba Building Trades Golf Tournament
Manitoba Hydro - Gillam Area Charitable Donation Committee
Manitoba Mustang’s Charity Hockey Fund - Garth Lancaster
A Mantella & Sons Ltd.
M. Ann Marshall
Mary and Gordon Christopher Foundation
Maria and Ralph Matheson
Claudia and Mike Mazzaferro
Alan Menkes
Menkes Developments
Howard Meyer
The Michael & Croyden Memorial Walk-JDRF
Mike LeBlanc and MBS Cycle 200
Ross Mikkelson – BBQ’s Galore
Steven Miller
Mills Office Productivity
Natalie Minckler
Harley Mintz
Bruce Mitchell and Vladka Kratochvilova
Mitchell-Lincoln Packaging Ltd.
MLS WORKS
Enzo Monticciolo
Rosalia Monticciolo and Family
Vincenzo Monticciolo
Moore Stephens Cooper Molyneux LLP
Morgan Stanley Canada Limited
Morguard Investments Limited
“Kids should be able to be kids. That’s why I support JDRF. When kids have to worry about injections, monitoring blood sugar levels and all of the other day-to-day nuisances of diabetes, they don’t get to experience the carefree nature of childhood. I support JDRF in hope that one day my contribution will make a positive impact, however big or small, on the lives of people living with type 1 diabetes.”
The Beta Society Legacy

Gift Honour Roll
The Estate of Arthur Agajanian
Richard Anstett
Marsha and Aubrey Baillie
The Estate of Stefania Baresic
The Estate of Jen Marie Bates
Margaret Louise Bell
The Estate of John Spencer Bigham
The Estate of Alice Bishop
M. Bjegovich
The Estate of Georgia Blanch
The Estate of Dorothy Bloomfield
The Estate of Joseph Blumethal
Maureen Brady
The Estate of Beverley Pearl Bridge
The Estate of Mabel E. Brooks
The Estate of Michael Brubacher
The Estate of H. Joyce Burtenshaw
The Estate of Pearl Caplan
The Estate of Robert Chisholm
The Estate of Edward Cohen
The Estate of Frances Corey
The Estate of Ron Courneyea
The Estate of Mary Elizabeth Courtice
Succession Ghislaine Daneau
The Estate of Inez Darragh
The Estate of Elizabeth Davidson
The Estate of Mary Elizabeth Debus
The Estate of Elizabeth Jean Dickson
Charlebois Dingle
The Estate of E. Doherty
The Estate of Ruby Driscoll
The Estate of Violet Beatrice Eburne
The Estate of Robert Milton Edgar
The Estate of Katherine Jerlien Elliott
The Estate of Nathan Finkelstein
The Estate of Diane Finsten
The Estate of Robert John Fischer
The Estate of George Fleming
The Estate of Margery A. Garland
The Estate of James Geddes
Succession Fedora Giroux Beaudoin
The Estate of Nathan Gold
The Estate of Winnifred Gray
The Estate of Irving Green
The Estate of Jessie Green
The Estate of Cécile Grobowsky c/o
c/o Helen Srayko
Carol and Larry Hagan
The Estate of Margaret E Hales
The Estate of Catherine Harkness
The Estate of Elizabeth Harris
The Estate of Margaret M. Harris
The Estate of Marianne Ava Hart
The Estate of B.T. Hazelton
The Estate of Florence Amelia Hill
The Estate of The Late Steven Hill
The Estate of Enos Victor Hodsdon
The Estate of Ernestine Hopkins
The Estate of Mrs. Audrey Hough
Succession Pauline Houle-Bergeron
The Estate of Helen Murphy House
The Estate of Thomas Asquith House
The Estate of John Hunter
Bonnie and Terry Jackson
The Estate of Lyle W. Jackson
The Estate of Edith Edna Johns
The Estate of Leah Kessler
Beverley Kinshella
The Estate of Doris Elisabeth Langille
The Estate of Renaude Lapointe
Dorothy and Donald Lawless
The Estate of Gladys J.A. Leggett
The Estate of Jean Templeton Lindsay
The Estate of Joseph Saul Lipes
The Estate of Jack David Lubotta
The Estate of Lucy Lynn
The Estate of Williamina Dorthy MacDonald
The Estate of James R Mallory
The Estate of Zabel Mancantelli
The Estate of Linton Maseko
The Estate of Myrtle Mawhood
The Estate of Myrtle Mawhood
The Estate of Donald Edward McCarthy
The Estate of Edna McDonald
The Estate of Catherine Douglas McEwen
Robert McLeish
The Estate of Peter Egerton Ryerson Miller
The Estate of Marjorie Elizabeth Robertson Misener
The Estate of Olive Mae Mueller
The Estate of Winnifred Bernice Muir
Paula Mussman
The Estate of Edward Nadler
The Estate of Donald Nattress
Carol and Michael Nedham
The Estate of Doris May Newman
The Estate of Helen Alice Nichols
The Estate of Hiroshi Nozuye
The Estate of Richard Oatway
The Estate of Graham Peter Owen
The Estate of Nellie Paskou
The Estate of Helen E. Peters
Christina Peterson
The Estate of Lawrence Plowman
Lorraine Pollock
The Estate of Edna Charron Presseau
The Estate of Helen Wetmore Redding
The Estate of Lillian Evelyn Reine Tannis and George Richardson
The Estate of Mary Margaret Riley
The Estate of Ernestine Robert
The Estate of Edith Rodier
The Estate of Agnes Rodvik
The Estate of Alan Samuels
The Estate of Theresa Helen Sansom
The Estate of Mathilda Sarettske
The Estate of Martha Serrels
The Estate of Martha Serrels
The Estate of Bonnie Sheldon
The Estate of Miriam Mary Sherman
Louise and Paul Shewfelt
Helaine and Allan Shiff
David Skelly
The Estate of Margaret Case Small
The Estate of Margaret Cunard Smith
The Estate of Reginald Smith
The Estate of Stella Solski
The Estate of Elizabeth Stewart
The Estate of Maureen Swaffer
The Estate of Virginia Tabraham
The Estate of In-chan Tai
Succession Jean Talbot
The Estate of Henry William Thomas Tansley
Margaret Taylor
The Estate of Vladimir Terleskey
The Estate of Rose Thomas
The Estate of Ronald Thornton
The Estate of Elizabeth Kate Tiffin
The Estate of Gisela Ulrich
The Estate of Adriana Christina Van Veen
The Estate of Arie Van Velzen
The Estate of Michael S. Vaughan
The Estate of Betty Ann Marion Vodden
The Estate of Annie Elizabeth Vogt
The Estate of Marion Golden Walker
The Estate of Mary Warkentin
The Estate of Mary Elizabeth Warren
The Estate of Donald Watt
The Estate of Ewrt M. Welsh
The Estate of Donald William
The Estate of Anna L Wilson
Dr. and Mrs. D. Wright
14 Anonymous
# Canadian Research Funded by JDRF

## Immune Therapies

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Grant Type</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danska, Jayne, PhD</td>
<td>Strategic Research Agreement</td>
<td>Mechanisms of Type 1 Diabetes Protection by Manipulation of Gut Microflora</td>
<td>The Hospital for Sick Children, Toronto, ON</td>
<td></td>
</tr>
<tr>
<td>Kieffer, Timothy, PhD</td>
<td>Strategic Research Agreement</td>
<td>Novel Biomarkers for Diabetes</td>
<td>University of British Columbia, Vancouver, BC</td>
<td></td>
</tr>
<tr>
<td>Santamaria, Pere, MD, PhD</td>
<td>Strategic Research Agreement</td>
<td>Expansion of autoregulatory CD4+ memory with pMHC class II nanoparticles</td>
<td>McGill University Health Centre-Montreal Children’s Hospital, Montreal, QC</td>
<td></td>
</tr>
<tr>
<td>Tan, Rusung, MD, PhD</td>
<td>Strategic Research Agreement</td>
<td>IL-17 in type 1 diabetes</td>
<td>University of British Columbia, Vancouver, BC</td>
<td></td>
</tr>
<tr>
<td>Verchere, C. Bruce, PhD</td>
<td>Strategic Research Agreement</td>
<td>Proteomic discovery of stem cell-secreted islet regenerative biomarkers</td>
<td>The University of Western Ontario, London, ON</td>
<td></td>
</tr>
<tr>
<td>Johnson, James, PhD</td>
<td>Priority Research Grant</td>
<td>High-Throughput analysis of beta-cell preserving paracrine factors</td>
<td>University of British Columbia, Vancouver, BC</td>
<td></td>
</tr>
<tr>
<td>MacDonald, Patrick, PhD</td>
<td>Career Development Award</td>
<td>Metabolic and immunologic interactions in islet graft function and loss</td>
<td>The Governors of the University of Alberta, Edmonton, AB</td>
<td></td>
</tr>
<tr>
<td>McBane, Joanne, PhD</td>
<td>Postdoctoral Fellowship Award</td>
<td>Using Biomatrices to Promote Angiogenesis in Islet Transplantation</td>
<td>Ottawa Heart Institute Research Corporation, Ottawa, ON</td>
<td></td>
</tr>
<tr>
<td>Screaton, Robert, PhD</td>
<td>Priority Research Grant</td>
<td>Functional Genomics of Human Beta Cell Proliferation</td>
<td>Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON</td>
<td></td>
</tr>
<tr>
<td>Shapiro, A.M. James, MD</td>
<td>Strategic Research Agreement</td>
<td>Caspase Inhibition in Clinical Islet Transplantation</td>
<td>University of Alberta- Dept. of Surgery, Edmonton, AB</td>
<td></td>
</tr>
<tr>
<td>Verchere, C. Bruce, PhD</td>
<td>Priority Research Grant</td>
<td>CCL22-Mediated Protection of Islet Transplants</td>
<td>University of British Columbia, Vancouver, BC</td>
<td></td>
</tr>
</tbody>
</table>
Knowing that there is world class type 1 cure research always being done is important to us. It gives us hope. When we decided to take the step to fund cure research ourselves, JDRF became a valuable partner. Their knowledge of the research community and their experience overseeing research projects has provided a lot of value to us as donors.
Management is responsible for the preparation of JDRF’s financial statements and other financial information in this report. This responsibility includes maintaining the integrity and objectivity of the financial records. JDRF maintains a system of internal controls designed to provide assurance that its records include the transactions of its operations.

The financial statements have been reported on by JDRF’s auditors, PricewaterhouseCoopers LLP, Chartered Accountants. The Board of Directors, through its Finance Committee, is responsible for determining that management fulfills its responsibilities in the preparation of the financial statements, and ensures the financial and operational controls of JDRF are adequate.

The Audit Committee reviews the financial statements and meets with the auditors. The auditors have full and free access to management, the Finance Committee, and the Audit Committee in carrying out their work.

The data on this page has been extracted and summarized from the audited financial statements. A complete set of financial statements is available on our website at jdrf.ca or upon request at 1.877.287.3533. Charitable business number: 11897 6604 RR0001.
Senior Leadership Team

Dave Prowten, President & CEO
Mary Ann Azzarello, Vice President, Development
Cindy Innes, Vice President, Support Services
Nancy Roper, Vice President Donor Relations
Jennifer McEvoy, Associate Vice President, Marketing and Communications

Board of Directors 2013/2014

Aubrey W. Baillie, Chair of the Board
Alex S. Davidson, Treasurer
Dr. David Kozloff, Secretary
Darrin Davis
Mary Jane Devine
Sheldon Finkelstein, MD
Bryan C. Haynes
Mike Hopkins
Judy M. Hunt
Garth Lancaster
Mollie Miller
Sean Murray
Peter Oliver
Maarika Paul
Ryan Shay
Lorne Shiff
Stephen Sibold
Matt Varey
Andrew Wilkin
Bruce Williams
Andrew McKee – Ex-Officio

Chapters and Locations

National Support Office
2550 Victoria Park Avenue, Suite 800
Toronto, ON M2J 5A9
Toll Free: 1.877.CURE.533

Toronto Region
Toronto Chapter
2550 Victoria Park Ave., Suite 800
Toronto, ON M2J 5A9
Tel: 647.789.2000

South Central Ontario Region
Peel Chapter
6620 Kitimat Road, Unit 1A
Mississauga, ON L5N 2B8
Tel: 905.608.8067

Barrie
109 Bayfield St.
Midhurst, ON L4M 3A9
Tel: 705.792.4833

Hamilton Chapter
12-442 Millen Road
Stoney Creek, ON L8E 6H2
Tel: 905.664.1432

North Eastern Ontario Region
Ottawa Chapter
1600 Merivale Road, Suite 206
Ottawa, ON K2G 5J8
Tel: 613.244.4818

South Western Ontario Region
Waterloo Chapter
684 Belmont Ave. W., Unit 103
Kitchener, ON N2M 1N6
Tel: 519.745.2426

London
309 Commissioners Rd. Unit A #2
London, ON N6J 1Y4
Tel: 519.641.7006

Windsor
261 Moceri Cres., Tecumseh, ON N8N 5A9
Tel: 519.739.9191

BC & Yukon Region
Vancouver Chapter
6450 Roberts St., Suite 150
Burnaby, BC V5G 4E1
Tel: 604.320.1937

Kamloops
347 West Seymour Street
Kamloops, BC V2C 1E8
Tel: 250.374.0599

Kelowna
PO Box 22037 Capri Centre
Kelowna, BC V1Y 9N9
Tel: 250.765.7711

Nanaimo
Tel: 250.370.7790

Victoria Chapter
1581-H Hillside Avenue, Suite 296
Victoria, BC V8T 2C1
Tel: 250.370.7790

Southern Alberta Region
Calgary Chapter
1608-17th Avenue S.W., Suite 204
Calgary, AB T2T 0E3
Tel: 403.255.7100

North Central Alberta & NWT Region
Edmonton Chapter
17312 – 107 Avenue NW
Edmonton, AB T5S 1E9
Tel: 780.428.0343

Red Deer
P.O. Box 25040 Deer Park
Red Deer, AB T4R 2H0
Tel: 855.428.0343

Prairie Region
Winnipeg Chapter
191 Lombard Avenue, Suite 1101
Winnipeg, MB R3B 0X1
Tel: 204.953.4477

Regina Chapter
P.O. Box 3924
Regina, SK S4P 3R8
Tel: 306.543.5451

Saskatoon Chapter
P.O. Box 22016
Prince Albert, SK S6V 8E3
Tel: 306.314.9533

Quebec Region
Montreal Chapter
615, boul. René-Lévesque Ouest, bureau 330
Montreal, QC H3B 1P5
Tel: 514.744.5537

Quebec City
881 Route 138
Neuveville, QC G0A 2R0
Tel: 581.983.7789

Atlantic Region
Halifax Chapter
1658 Bedford Highway, Suite 2055
Bedford Place Mall
Bedford, NS B4A 2X9
Tel: 902.453.1009

Moncton
36 Albert Street,
Moncton, NB E1C 1A9
Tel: 506.857.4254

Saint John, NB
99 Hampton Road
Rothesay, NB E2E 3L3
Tel: 506.763.0001

St. John’s, NL
6 Islington Place
Paradise, NL A1L 0H1
Tel: 709.237.6855